Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Evidence gaps in the management of sickle cell disease: A summary of needed research.

Savage WJ, Buchanan GR, Yawn BP, Afenyi-Annan AN, Ballas SK, Goldsmith JC, Hassell KL, James AH, John-Sowah J, Jordan L, Lottenberg R, Murad MH, Ortiz E, Tanabe PJ, Ware RE, Lanzkron SM.

Am J Hematol. 2015 Apr;90(4):273-5. doi: 10.1002/ajh.23945. Epub 2015 Feb 17. No abstract available.

2.

Inferior vena cava filters in trauma patients: a national practice patterns survey of U.S. Trauma centers.

Rajasekhar A, Elmariah H, Lottenberg L, Beyth R, Lottenberg R, Ang D.

Am Surg. 2014 Dec;80(12):1237-44.

PMID:
25513923
3.

Update on the use of hydroxyurea therapy in sickle cell disease.

Wong TE, Brandow AM, Lim W, Lottenberg R.

Blood. 2014 Dec 18;124(26):3850-7; quiz 4004. doi: 10.1182/blood-2014-08-435768. Epub 2014 Oct 6. Review. No abstract available.

4.

Approach to the diagnosis and treatment of acute subarachnoid hemorrhage in a patient with sickle cell disease.

Lyon M, Jeter J, Lottenberg R.

Am J Emerg Med. 2015 Mar;33(3):481.e3-4. doi: 10.1016/j.ajem.2014.08.068. Epub 2014 Aug 29.

PMID:
25256268
5.

Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.

Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, Jordan L, Lanzkron SM, Lottenberg R, Savage WJ, Tanabe PJ, Ware RE, Murad MH, Goldsmith JC, Ortiz E, Fulwood R, Horton A, John-Sowah J.

JAMA. 2014 Sep 10;312(10):1033-48. doi: 10.1001/jama.2014.10517. Review. Erratum in: JAMA. 2014 Nov 12;312(18):1932. JAMA. 2015 Feb 17;313(7):729.

PMID:
25203083
6.

Practice guideline for pulmonary hypertension in sickle cell: direct evidence needed before universal adoption.

Hassell KL, Afenyi-Annan A, Ballas SK, Buchanan GR, Eckman JR, Jordan L, Lanzkron S, Lottenberg R, Ware R.

Am J Respir Crit Care Med. 2014 Jul 15;190(2):237-8. doi: 10.1164/rccm.201404-0640LE. No abstract available.

PMID:
25025359
7.

Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia.

Murphy M, Close J, Lottenberg R, Rajasekhar A.

Am J Med Sci. 2014 Mar;347(3):254-5. doi: 10.1097/MAJ.0000000000000228. No abstract available.

PMID:
24553361
8.

Drug-loaded sickle cells programmed ex vivo for delayed hemolysis target hypoxic tumor microvessels and augment tumor drug delivery.

Choe SW, Terman DS, Rivers AE, Rivera J, Lottenberg R, Sorg BS.

J Control Release. 2013 Oct 28;171(2):184-92. doi: 10.1016/j.jconrel.2013.07.008. Epub 2013 Jul 18.

9.

Transfusion practices in the management of sickle cell disease: a survey of Florida hematologists/oncologists.

Dunbar LN, Coleman Brown L, Rivera DR, Hartzema AG, Lottenberg R.

ISRN Hematol. 2012;2012:524513. doi: 10.5402/2012/524513. Epub 2012 Dec 12.

10.

Hydroxyurea use in patients with sickle cell disease in a Medicaid population.

Ritho J, Liu H, Hartzema AG, Lottenberg R.

Am J Hematol. 2011 Oct;86(10):888-90. doi: 10.1002/ajh.22134. Epub 2011 Aug 22. No abstract available.

11.

A pilot study on the randomization of inferior vena cava filter placement for venous thromboembolism prophylaxis in high-risk trauma patients.

Rajasekhar A, Lottenberg L, Lottenberg R, Feezor RJ, Armen SB, Liu H, Efron PA, Crowther M, Ang D.

J Trauma. 2011 Aug;71(2):323-8; discussion 328-9. doi: 10.1097/TA.0b013e318226ece1.

PMID:
21825934
12.

Survival of trauma patients after massive red blood cell transfusion using a high or low red blood cell to plasma transfusion ratio.

Rajasekhar A, Gowing R, Zarychanski R, Arnold DM, Lim W, Crowther MA, Lottenberg R.

Crit Care Med. 2011 Jun;39(6):1507-13. doi: 10.1097/CCM.0b013e31820eb517. Review.

PMID:
21336132
13.

Pulmonary embolism prophylaxis with inferior vena cava filters in trauma patients: a systematic review using the meta-analysis of observational studies in epidemiology (MOOSE) guidelines.

Rajasekhar A, Lottenberg R, Lottenberg L, Liu H, Ang D.

J Thromb Thrombolysis. 2011 Jul;32(1):40-6. doi: 10.1007/s11239-010-0544-7. Review.

PMID:
21221716
14.

Bacterial adaptation and infection.

Boyle MD, Lottenberg R.

Inflamm Allergy Drug Targets. 2010 Sep;9(4):238-48. Review.

PMID:
20887271
15.

Nonmalignant blood disorders: time to establish a public health agenda.

Lottenberg R.

Am J Prev Med. 2010 Apr;38(4 Suppl):S449-50. doi: 10.1016/j.amepre.2010.01.014. No abstract available.

PMID:
20331941
16.

Thrombotic storm in Kimura disease.

Liu H, Al-Quran SZ, Lottenberg R.

J Thromb Thrombolysis. 2010 Apr;29(3):354-7. doi: 10.1007/s11239-009-0346-y. Epub 2009 May 26.

PMID:
19468829
17.

Development and evaluation of a patient empowerment video to promote hydroxyurea adoption in sickle cell disease.

LaVista JM, Treise DM, Dunbar LN, Ritho J, Hartzema AG, Lottenberg R.

J Natl Med Assoc. 2009 Mar;101(3):251-7.

PMID:
19331257
18.

Cocaine abuse complicating acute painful episodes in sickle cell disease.

Boulmay B, Lottenberg R.

South Med J. 2009 Jan;102(1):87-8. doi: 10.1097/SMJ.0b013e318188b2ab.

PMID:
19077772
19.

Rituximab-induced hypersensitivity pneumonitis.

Tonelli AR, Lottenberg R, Allan RW, Sriram PS.

Respiration. 2009;78(2):225-9. doi: 10.1159/000163069. Epub 2008 Oct 9.

20.

Blood bank management of sickle cell patients at comprehensive sickle cell centers.

Afenyi-Annan A, Willis MS, Konrad TR, Lottenberg R.

Transfusion. 2007 Nov;47(11):2089-97.

PMID:
17958539
21.

Acute liver failure occurring immediately following anti-D immune globulin infusion in a patient with chronic hepatitis B infection.

Abdelmalek MF, Hellner LB, Zumberg M, Melgen VW, Lottenberg R.

Dig Dis Sci. 2007 Apr;52(4):914-9. Epub 2007 Mar 9. No abstract available.

PMID:
17347887
22.

Chronic oral anticoagulant therapy for extrahepatic visceral thrombosis is safe.

Kitchens CS, Weidner MH, Lottenberg R.

J Thromb Thrombolysis. 2007 Jun;23(3):223-8.

PMID:
17221331
23.

Opportunities to improve outcomes in sickle cell disease.

Mehta SR, Afenyi-Annan A, Byrns PJ, Lottenberg R.

Am Fam Physician. 2006 Jul 15;74(2):303-10. Review.

24.

An evidence-based approach to the treatment of adults with sickle cell disease.

Lottenberg R, Hassell KL.

Hematology Am Soc Hematol Educ Program. 2005:58-65.

PMID:
16304360
25.

Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/oncologists.

Zumberg MS, Reddy S, Boyette RL, Schwartz RJ, Konrad TR, Lottenberg R.

Am J Hematol. 2005 Jun;79(2):107-13.

26.

Pneumococcal vaccines for sickle cell disease.

Davies EG, Riddington C, Lottenberg R, Dower N.

Cochrane Database Syst Rev. 2004;(1):CD003885. Review.

PMID:
14974042
27.

Role of phlebotomy in the management of hemoglobin SC disease: case report and review of the literature.

Markham MJ, Lottenberg R, Zumberg M.

Am J Hematol. 2003 Jun;73(2):121-5. Review.

28.

A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/L versus 20,000/microL trigger.

Zumberg MS, del Rosario ML, Nejame CF, Pollock BH, Garzarella L, Kao KJ, Lottenberg R, Wingard JR.

Biol Blood Marrow Transplant. 2002;8(10):569-76.

29.

Racial and ethnic composition of volunteer cord blood donors: comparison with volunteer unrelated marrow donors.

Ballen KK, Hicks J, Dharan B, Ambruso D, Anderson K, Bianco C, Bemiller L, Dickey W, Lottenberg R, O'Neill M, Popovsky M, Skerrett D, Sniecinski I, Wingard JR.

Transfusion. 2002 Oct;42(10):1279-84.

PMID:
12423511
30.

Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report.

Aranda JM Jr, Scornik JC, Normann SJ, Lottenberg R, Schofield RS, Pauly DF, Miles M, Hill JA, Sleasman JW, Skoda-Smith S.

Transplantation. 2002 Mar 27;73(6):907-10.

PMID:
11923690
31.

Autoantibody formation in the alloimmunized red blood cell recipient: clinical and laboratory implications.

Zumberg MS, Procter JL, Lottenberg R, Kitchens CS, Klein HG.

Arch Intern Med. 2001 Jan 22;161(2):285-90.

PMID:
11176745
32.

The interaction of pathogens with humans.

Boyle MD, Lottenberg R.

Methods. 2000 Jun;21(2):99-102. No abstract available.

PMID:
10816370
33.
34.
36.

Microbes, hemostasis and vascular biology.

Lottenberg R, Höök M, Walker D.

Trends Microbiol. 1998 Nov;6(11):428-9. No abstract available.

PMID:
9846354
37.

Ischemic colitis and acquired resistance to activated protein C in a woman using oral contraceptives.

Mann DE Jr, Kessel ER, Mullins DL, Lottenberg R.

Am J Gastroenterol. 1998 Oct;93(10):1960-2.

PMID:
9772065
39.

A novel approach to explore the role of plasminogen in bacterial pathogenesis.

Lottenberg R.

Trends Microbiol. 1997 Dec;5(12):466-7; discussion 468. Review. No abstract available.

PMID:
9447656
40.

Chronic relapsing thrombotic thrombocytopenic purpura and antiphospholipid antibodies: a report of two cases.

Trent K, Neustater BR, Lottenberg R.

Am J Hematol. 1997 Feb;54(2):155-9. Review.

41.

Plasminogen activation by invasive human pathogens.

Boyle MD, Lottenberg R.

Thromb Haemost. 1997 Jan;77(1):1-10. Review.

PMID:
9031440
42.

Contact activation proteins and the bacterial surface.

Lottenberg R.

Trends Microbiol. 1996 Nov;4(11):413-4; discussion 414-5. Review. No abstract available.

PMID:
8950805
43.
44.

Analysis of the interaction of group A streptococci with fibrinogen, streptokinase and plasminogen.

Wang H, Lottenberg R, Boyle MD.

Microb Pathog. 1995 Mar;18(3):153-66.

PMID:
7565010
45.

Mutational analysis of a plasmin receptor protein expressed by group A streptococci.

Winram SB, Richardson LC, Lottenberg R.

Dev Biol Stand. 1995;85:199-202. No abstract available.

PMID:
8586176
46.

A role for fibrinogen in the streptokinase-dependent acquisition of plasmin(ogen) by group A streptococci.

Wang H, Lottenberg R, Boyle MD.

J Infect Dis. 1995 Jan;171(1):85-92.

PMID:
7798686
47.

Characterization of a novel streptokinase produced by Streptococcus equisimilis of non-human origin.

Nowicki ST, Minning-Wenz D, Johnston KH, Lottenberg R.

Thromb Haemost. 1994 Oct;72(4):595-603.

PMID:
7878639
48.
49.

Capturing host plasmin(ogen): a common mechanism for invasive pathogens?

Lottenberg R, Minning-Wenz D, Boyle MD.

Trends Microbiol. 1994 Jan;2(1):20-4. Review.

PMID:
8162432
50.

Streptokinase-producing streptococci grown in human plasma acquire unregulated cell-associated plasmin activity.

Lottenberg R, DesJardin LE, Wang H, Boyle MD.

J Infect Dis. 1992 Aug;166(2):436-40.

PMID:
1386099

Supplemental Content

Loading ...
Support Center